Physician profile
Anisa Valina
NPI 1659719854
$308.34
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $18.32 · 2021: $120.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $107.62 | 2021 | |
| Abiomed | $103.39 | 2019 | |
| Astellas Pharma US INC | $39.99 | 2019 | |
| Genzyme Corporation | $18.32 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $15.18 | 2019 | |
| Boston Scientific Corporation | $12.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.51 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anisa Valina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.